Selling, general and administrative expenses decreased 4% and 2% for the three and six months ended June 30, 2026, compared to 2025, respectively, due to reduced headcount-related costs and lower spending as part of our cost-saving and restructuring initiatives.

filing / Jul 31, 2026 / receipt

Research and development expenses decreased 5% for each of the three and six months ended June 30, 2026, compared to 2025, primarily due to reduced headcount-related costs related to our restructuring initiatives and a decrease in clinical study activity.

filing / Jul 31, 2026 / receipt

Based on this evaluation, the CEO and the CFO concluded that our disclosure controls and procedures were effective as of June 30, 2026 at the reasonable assurance level.

filing / Jul 31, 2026 / receipt

For the three months ended March 31, 2026, we incurred restructuring costs of $31 million related to our 2026 restructuring initiatives to streamline and optimize our research and development and manufacturing operations, focusing on enhancing efficiency and aligning resources with strategic priorities.

filing / May 4, 2026 / receipt

For the three months ended March 31, 2025, we incurred restructuring costs of $86 million, comprised primarily of headcount-related restructuring expense associated with restructuring initiatives that were aimed at driving operational efficiencies in 2025.

filing / May 4, 2026 / receipt

Based on this evaluation, the CEO and the CFO concluded that our disclosure controls and procedures were not effective as of March 31, 2026, due to the material weaknesses in internal control over financial reporting as described below.

filing / May 4, 2026 / receipt

We could also be required to raise capital via equity transactions (which may be dilutive to existing investors or provide new investors with rights, preferences, or privileges senior to our common stock), sale of significant assets, and significant cost reduction measures.

filing / May 4, 2026 / receipt

Medical Science Liaison - Michigan/Indiana | {"ats": "workday", "city": null, "state": null, "job_id": "/job/USA---Michigan---Detroit/Medical-Science-Liaison---Michigan-Indiana_R542519-1", "remote": f

company_statement / Sep 16, 2026 / receipt

Sr. Specialist, Business Ownership & Compliance Governance | {"ats": "workday", "city": null, "state": null, "job_id": "/job/BRA---Sao-Paulo/Sr-Specialist--Business-Ownership---Compliance-Governance_R

company_statement / Sep 15, 2026 / receipt

AVP, Quality Systems & Compliance | {"ats": "workday", "city": null, "state": null, "job_id": "/job/CHE---Lucerne---Weystrasse/AVP--Quality-Systems---Compliance_R542344-1", "remote": false, "category"

company_statement / Sep 15, 2026 / receipt

Promotion Manager | {"ats": "workday", "city": null, "state": null, "job_id": "/job/CHN---Shanghai---Shanghai/Promotion-Manager_R541923-1", "remote": false, "category": "other", "function": "other", "

company_statement / Sep 15, 2026 / receipt

Intern - Demand Fulfilment Planning | {"ats": "workday", "city": null, "state": null, "job_id": "/job/SGP---Singapore---Singapore/Intern---Demand-Fulfilment-Planning_R542365-1", "remote": false, "cate

company_statement / Sep 15, 2026 / receipt